A STUDY OF SERUM IMMUNOGLOBULIN LEVELS IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING STANDARD INDUCTION CHEMOTHERAPY

Document Type : Preliminary preprint short reports of original research

Authors

1 Department of Hematology, Alexandria University

2 Hematology Unit, Department of Internal Medicine, Faculty of Medicine, Alexandria University

3 Department of Physical Medicine, Rheumatology and Rehabilitation, Faculty of medicine, Alexandria university, Egypt.

Abstract

Acute myeloid leukemia (AML) is a heterogenous malignant disease caused by an impaired differentiation of hematopoietic stem cells into myeloid cells leading to accumulation of immature blast cells in the bone marrow (BM), the peripheral blood (PB) and rarely other organs. AML accounts for 80% of adult acute leukemia and is primarily a disease of older adults with an annual incidence rate of 20.1 per 100,000 population in those aged above 65 years.
Induction chemotherapy with anthracycline and cytarabine, is the mainstay for treatment of AML; all trans retinoic acid (ATRA) or arsenic trioxide (ATO) are added in Acute Promyelocytic Leukemia cases (APL). However, induction chemotherapy also induces more prolonged neutropenia in AML patients, favoring infectious complications and deaths. Immunoglobulins (Ig) are produced by B-cells in response to bacteria, viruses, fungi, parasites, cellular antigens, chemicals, and synthetic substances. Decreased serum immunoglobulin levels are associated with lower survival rate in septic patients.

Keywords

ALEXMED ePosters
Volume 5, Issue 4
December 2023
Pages 31-32

Files

Share

How to cite

Statistics